These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 35593784)

  • 1. Triptans and vascular comorbidity in persons over fifty: Findings from a nationwide insurance database - A cohort study.
    Zebenholzer K; Gall W; Gleiss A; Pavelic AR; Wöber C
    Headache; 2022 May; 62(5):604-612. PubMed ID: 35593784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triptan use and risk of cardiovascular events: a nested-case-control study from the French health system database.
    Lugardon S; Roussel H; Sciortino V; Montastruc JL; Lapeyre-Mestre M
    Eur J Clin Pharmacol; 2007 Aug; 63(8):801-7. PubMed ID: 17576547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use and overuse of triptans in Austria - a survey based on nationwide healthcare claims data.
    Zebenholzer K; Gall W; Wöber C
    J Headache Pain; 2018 May; 19(1):34. PubMed ID: 29777424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying the factors underlying discontinuation of triptans.
    Wells RE; Markowitz SY; Baron EP; Hentz JG; Kalidas K; Mathew PG; Halker R; Dodick DW; Schwedt TJ
    Headache; 2014 Feb; 54(2):278-89. PubMed ID: 24001117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential Channeling Bias in the Evaluation of Cardiovascular Risk: The Importance of Comparator Selection in Observational Research.
    Li H; Mawanda F; Mitchell L; Zhang X; Goodloe R; Vincent M; Motsko S
    Pharmaceut Med; 2022 Aug; 36(4):247-259. PubMed ID: 35788962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in Triptan Usage in Korea: A Population-Based Cohort Study.
    Ha WS; Jeong J; Song S; Yum J; Chu MK
    J Korean Med Sci; 2024 Aug; 39(31):e222. PubMed ID: 39137809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of NSAID and Triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.
    Lipton RB; Serrano D; Nicholson RA; Buse DC; Runken MC; Reed ML
    Headache; 2013; 53(10):1548-63. PubMed ID: 23992516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health care resource utilization following initiation of a triptan: a retrospective claims analysis.
    Messali A; Owens G; Bloudek L; Kori S; Cole A; Chia J
    J Manag Care Spec Pharm; 2014 Apr; 20(4):368-75. PubMed ID: 24684641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of Stroke and Myocardial Infarction Among Initiators of Triptans.
    Petersen CL; Hougaard A; Gaist D; Hallas J
    JAMA Neurol; 2024 Mar; 81(3):248-254. PubMed ID: 38315477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response.
    Marcus SC; Shewale AR; Silberstein SD; Lipton RB; Young WB; Viswanathan HN; Doshi JA
    Cephalalgia; 2020 Jun; 40(7):639-649. PubMed ID: 32223301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Patterns of prescription and usage of triptans in Alsace (France): misuse is frequent and avoidable].
    Perearnau P; Vuillemet F; Schick J; Weill G
    Rev Neurol (Paris); 2006 Mar; 162(3):347-57. PubMed ID: 16585890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perinatal use of triptans and other drugs for migraine-A nationwide drug utilization study.
    Tauqeer F; Wood M; Hjorth S; Lupattelli A; Nordeng H
    PLoS One; 2021; 16(8):e0256214. PubMed ID: 34424941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twenty-five years of triptans - a nationwide population study.
    Davidsson OB; Olofsson IA; Kogelman LJ; Andersen MA; Rostgaard K; Hjalgrim H; Olesen J; Hansen TF
    Cephalalgia; 2021 Jul; 41(8):894-904. PubMed ID: 33583217
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Martínez-Pías E; García-Azorín D; Minguez-Olaondo A; Trigo J; Sierra Á; Ruiz M; Guerrero ÁL
    Expert Rev Neurother; 2021 Jan; 21(1):123-130. PubMed ID: 33111580
    [No Abstract]   [Full Text] [Related]  

  • 15. Coprescription of triptans with potentially interacting medications: a cohort study involving 240,268 patients.
    Tepper S; Allen C; Sanders D; Greene A; Boccuzzi S
    Headache; 2003 Jan; 43(1):44-8. PubMed ID: 12864757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmaceutically treated comorbidities and associated healthcare costs among triptan users in Switzerland: A pharmacoepidemiological study from a nationwide health insurance database.
    Huber CA; Agosti R; Näpflin M; Blozik E
    Pharmacoepidemiol Drug Saf; 2020 Mar; 29(3):279-287. PubMed ID: 31828875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triptan persistency among newly initiated users in a pharmacy claims database.
    Katić BJ; Rajagopalan S; Ho TW; Chen YT; Hu XH
    Cephalalgia; 2011 Mar; 31(4):488-500. PubMed ID: 20937605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of a 2-year retrospective cohort study of newly prescribed triptan users in European nationwide practice databases.
    Ng-Mak DS; Chen YT; Ho TW; Stanford B; Roset M
    Cephalalgia; 2012 Sep; 32(12):875-87. PubMed ID: 22833612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triptans use and overuse: A pharmacoepidemiology study from the French health insurance system database covering 4.1 million people.
    Braunstein D; Donnet A; Pradel V; Sciortino V; Allaria-Lapierre V; Lantéri-Minet M; Micallef J
    Cephalalgia; 2015 Nov; 35(13):1172-80. PubMed ID: 25667299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Geographic variation in the use of triptans and opioids for the acute treatment of migraine attacks.
    Lee JH; Shewale AR; Barthold D; Devine B
    Headache; 2021 Nov; 61(10):1499-1510. PubMed ID: 34841520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.